Trial abstract · §3
DANU-PH2B-T2D — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline to week 16 | Glycaemic effect demonstrated; the programme was discontinued for tolerability and hepatic-safety reasons | Not rated |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Danuglipron from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 73.0 | 18.0 | Phase 2b obesity, highest dose |
| Vomiting | 47.0 | 6.0 | Phase 2b obesity |
| Diarrhoea | 25.0 | 12.0 | Phase 2b obesity |
| Discontinuation for adverse events | 50.0 | 40.0 | Phase 2b obesity — high in both arms |
| Hepatic transaminase elevation | — | — | A case of drug-induced liver injury contributed to the discontinuation decision |
Compound Evidence Institute · CEI-TR-0069/3 · https://compoundevidence.com/trials/danu-ph2b-t2d/results/ · retrieved 30 July 2026